Tuesday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • Beckers Payer Issues tells us,
    • “House Minority Leader Hakeem Jeffries, D-NY, has endorsed lowering the Medicare eligibility age and expanding the program’s benefits, along with guaranteeing health coverage for all children. 
    • “Speaking at a Nov. 17 press conference on Capitol Hill, Mr. Jeffries said Democrats would first move next year to reverse the Medicaid cuts enacted under HR 1 and reinstate the enhanced ACA premium subsidies that expired at the end of 2025, priorities the party had previously outlined as part of its first-100-days plan. 
    • “A return to the status quo is not acceptable,” Mr. Jeffries told reporters. “We should lower the age of Medicare eligibility. We should expand coverage to include vision, hearing and dental. And we should cover all the kids in the United States of America. Those are bold actions, meaningful actions, important actions that can be taken on our march toward universal health coverage.”
    • “Mr. Jeffries, who is widely expected to become the next speaker of the House on Jan. 3, didn’t say what age he would support lowering the Medicare eligibility threshold to, but the endorsement goes further than the healthcare agenda House Democrats had laid out ahead of the midterms.”
  • Per a Senate Judiciary Committee news release,
    • “Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) today chaired a hearing to examine the high cost of prescription drugs and proposed legislative solutions. Last year, the Judiciary Committee advanced six Grassley-backed, bipartisan bills to lower prescription drug prices through competition transparency and to address anticompetitive tactics in the pharmaceutical supply chain. One of those bills, the Affordable Prescriptions for Patients Act, passed the Senate unanimously in July. The remaining bills have not received a vote on the Senate floor.
    • “Today’s witnesses urged Congress to pass bipartisan legislation and echoed Grassley’s calls for the Federal Trade Commission (FTC) to complete its 6(b) study of pharmacy benefit managers (PBMs).” 
  • Per STAT News,
    • “The Trump administration is pulling its nominee to lead the Food and Drug Administration, Heidi Overton, according to a White House official and a source close to Overton.
    • “The decision follows concerns that Overton, a preventive care doctor who previously served in the Trump White House, lacked sufficient support from Republicans on the Senate’s health panel, which had been expected to vote on her nomination Wednesday.”
  • The Wall Street Journal reports,
    • “President Trump’s nominee to lead the Government Accountability Office, Eric Ueland, is facing concerns from several Senate Republicans.
    • “Republican Senators Thom Tillis, Susan Collins and John Curtis have raised concerns about moving a White House budget official into the GAO role.
    • “Critics and Democrats argue that Eric Ueland is too partisan and that the nomination process bypassed the required bipartisan consultation.”
  • Today, two weeks after election day, the Centers for Medicare and Medicaid Services “released the 2027 Medicare Part A and Part B programs premiums, deductibles, and coinsurance, and the 2027 Medicare Part D income-related monthly adjustment amounts.” * * *
    • “The Medicare Part A inpatient hospital deductible that beneficiaries pay if admitted to the hospital will be $1,776 in 2027, an increase of $40 from $1,736 in 2026.” * * *
    • “The standard monthly premium for Medicare Part B enrollees will be $209.40 for 2027, an increase of $6.50 from $202.90 in 2026. The annual deductible for all Medicare Part B beneficiaries will be $292 in 2027, an increase of $9 from the annual deductible of $283 in 2026.” 
       
  • CMS adds,
    • Helping doctors, hospitals, and other healthcare providers work together is paying off for Medicare and taxpayers, with the largest savings in the Medicare Shared Savings Program’s history. The program yielded more than $2.5 billion in net savings to Medicare in 2025, marking its ninth consecutive year of saving taxpayer dollars. These results underscore the promise of accountable care — bringing healthcare providers together around patients’ needs while rewarding quality and reducing unnecessary spending.
    • In 2025, every participating Accountable Care Organization (ACO) met or exceeded Medicare’s quality reporting requirements, underscoring continued focus on providing better care and improved health outcomes.
  • Per an Department of Health and Human Services news release,
    • “The U.S. Department of Health and Human Services (HHS), through the Administration for Community Living (ACL), today announced a cooperative agreement totaling more than $3 million to USAging for the National Resource Center on Nutrition and Aging (NRCNA). The three-year award will strengthen Senior Nutrition Programs, funded by the Older Americans Act, by providing national leadership, training, technical assistance, data infrastructure, and resources that help communities improve nutrition services for older adults.”
  • Healthcare Dive adds its perspective on yesterday’s final rule amending the HIPAA Privacy Rule.
    • “HHS Office for Civil Rights Director Paula Stannard said she’s “convinced” the rule will enable health data sharing and better care coordination.”

From the U.S. Office of Personnel Management front,

  • Beckers Payer Issues picks up on the GLP-1 drug coverage changes in the FEHB and PSHB Programs for 2027.
  • Legis1 tells us,
    • “Phased retirement, which allows eligible federal employees to work half-time while drawing part of their pension, remains limited in use, according to a new Congressional Research Service (CRS) report. ​
    • “Data from the Office of Personnel Management (OPM) counted 1,533 initial phased retirements and 1,375 composite retirements from Nov. 6, 2014, through Oct. 13, 2026. That left 158 employees in phased retirement status as of Oct. 13, 2026.
    • Six agencies have each have had more than 100 participants [cumulatively], with the National Aeronautics and Space Administration reporting the most, at 222.
    • Participation depends on agency approval. CRS notes that phased retirement is not an entitlement and that not all federal agencies offer the program.”

From the U.S. Food and Drug Administration front,

  • Cardiovascular Business reports,
    • “One lot of generic propranolol hydrochloride extended-release capsules has been recalled due to a potential risk metal contamination. New Jersey-based Breckenridge Pharmaceutical issued a statement about the recall, highlighting the risks of consuming these capsules.
    • “Propranolol hydrochloride is a beta-blocker often prescribed to treat hypertension or arrhythmias. It has also been known to reduce migraine symptoms due to its effect on blood vessels in the brain. Propranolol hydrochloride has been sold under various brand names, but this specific recall is for one lot of a generic version of the drug.
    • “Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach or intestine,” the company explained. “The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market.”
    • “Breckenridge Pharmaceutical emphasized that no adverse events have been linked to this issue. However, due to the risk, the company is urging patients to “immediately stop” taking the capsules and reach out to a healthcare provider for “medical advice and replacement instructions.” Patients have also been asked to return any unused medications to where they originally obtained them.” 
  • Per FDA news releases,
    • “The U.S. Food and Drug Administration today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA’s regulatory drug and biologic approval decisions are leveraged by health authorities around the world. The GRDP marks a major step forward in the FDA’s global leadership and may accelerate patient access to innovative therapies throughout the world.
    • “The GRDP enables the FDA to more efficiently share minimally redacted approval packages, including the FDA’s detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside of the United States, empowering those authorities to rely on the FDA’s rigorous, science-based review decisions rather than conducting duplicative and time-consuming product evaluations of their own, while maintaining sovereignty over their regulatory decision.”
  • and
    • “The U.S. Food and Drug Administration today approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer. Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile-onset NPC.
    • “For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” said Acting FDA Commissioner Kyle Diamantas, J.D. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”
  • Fierce Pharma relates,
    • “On a hot streak, GSK has won a third high-profile FDA approval in recent weeks, this time for the second lung cancer drug from the British pharma’s $10.6 billion acquisition of Nuvalent earlier this year.
    • “Marking just the second commercial lung cancer drug in GSK’s history, the FDA has clearedNelkarmi, or neladalkib, for previously treated ALK-positive non-small cell lung cancer (NSCLC).
    • “Compared with the company’s first lung cancer approval, gained in July for legacy Nuvalent’s Jideytro in ROS1-positive NSCLC, Nelkarmi targets a larger patient population and carries greater commercial potential. When Royalty Pharma acquired a royalty interest in the two drugs at the end of 2025, it cited analysts’ consensus sales projections of $3.5 billion for Nelkarmi by 2035, versus $1.9 billion for Jideytro.”
  • MedTech Dive tells us,
    • “Medtronic said Tuesday the Food and Drug Administration has cleared the Hugo robotic system for use in general surgery procedures.
    • “The clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia and small bowel resection. Two lower abdominal procedures, inguinal hernia and appendectomy, were also cleared. 
    • “Medtronic said the combined procedures account for about 3.5 million annual surgeries in the U.S., or more than half of the soft tissue procedures performed each year.”

From the public health and medical / Rx research front,

  • The American Hospital Association News reports,
    • “The United States has lost its elimination status for measles, the Pan American Health Organization announced Nov. 17. The group, which is a regional arm of the World Health Organization, determined that the virus has sustained transmission for more than a year. The U.S. earned its elimination status designation in 2000. As of Nov. 12, there have been 5,412 confirmed cases of measles in the U.S. this year, according to the Centers for Disease Control and Prevention.” 
  • Beckers Clinical Leadership adds,
    • “During U.S. measles outbreaks from Jan. 1, 2025, to Sept. 28, 2026, 112 pregnant women were infected and 13 babies were born with congenital measles, according to a preliminary CDC analysis published Nov. 16 in NEJM Evidence. 
    • “It is the first national picture of measles complications in pregnancy in decades, assembled as the virus surged to its highest levels since the disease was declared eliminated in the U.S.
    • “Almost all of the infected women — 98% — had not received the measles-mumps-rubella vaccine before pregnancy or had an unknown vaccination status. Because MMR is a live vaccine that is not given during pregnancy, protection in this group depends on vaccination before pregnancy and high community coverage, the authors wrote.
    • “Twenty-six of the 112 women, or 23%, were hospitalized for reasons unrelated to labor. Eleven developed pneumonia; two had respiratory failure and one was admitted to the ICU, according to the CDC scientists’ findings as reported by The Washington Post.” * * *
    • “The report urges clinicians to prepare emergency departments, labor-and-delivery units and NICUs for cases many have never seen, to give unvaccinated exposed pregnant patients immune globulin within six days of exposure, and to administer immune globulin to exposed newborns at birth.”
  • On the bright side, Beckers Clinical Leadership relates,
    • “The U.S. five-year survival rate for lung cancer has increased from 18.1% in 2018 to 31%, according to the American Lung Association’s 2026 “State of Lung Cancer” report published Nov. 16.
    • “Despite nationwide improvement, lung cancer is still the leading cause of cancer deaths in the U.S., and survival rates were considerably lower across states and among certain racial and ethnic groups.
    • “We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis,” Harold Wimmer, president and CEO of the American Lung Association, said in a Nov. 16 news release from the American Lung Association.” 
  • Per a CDC news release,
    • “New CDC surveillance data show that the rate of new diabetes cases among U.S. adults increased from 2020 through 2025 after decreasing for more than a decade. 
    • “CDC is continuing research to identify factors contributing to this trend. Potential contributing factors include a change in screening practices that may result in more detection of previously undiagnosed diabetes and lifestyle changes during the COVID-19 pandemic that could increase risk for type 2 diabetes. Additionally, as the population ages, this demographic shift could contribute to an upward trend in the number of people with newly diagnosed diabetes. Adults 45 and older face higher risk for type 2 diabetes.
    • “It’s important that people know their risk for diabetes, take steps to prevent or delay type 2 diabetes, and manage diabetes if they already have it. 
    • “Resources include:
  • The American Medical Association lets us know,
    • “Pancreatic cancer will become the second-leading cause of cancer-related death in the U.S. by 2030. About 10% to 15% of those pancreatic cancers originate from cysts. While it sounds ominous, “it’s something that we can actually intervene upon before it has the opportunity to turn into cancer,” according to Christopher Chapman, MD, a gastroenterologist with Rush University System for Health in Chicago. 
    • Pancreatic cysts are extremely common but often cause anxiety for patients. Standard treatment usually involves surveillance imaging such as MRIs or CT scans, endoscopic procedures, or more invasive surgery.
    • “Rush is one of the few hospitals in the country and the only facility in Illinois that has been pioneering a chemoablation method for treating pancreatic cysts that pose a cancer risk. Under this procedure, physicians use endoscopic ultrasound to place a fine needle directly into the cyst to inject targeted chemotherapy.  
    • “Initially the words ‘chemo’ make patients feel unsettled, but because only a small volume is placed directly into the cyst, there is no additional risk for the significant side effects that people typically think of.  Due to its safety and effectiveness, we felt that patients in the Chicagoland area and in the Midwest in general should have the opportunity to access this novel approach close to home,” said Dr. Chapman, who joined Rush gastroenterologist Neal Mehta, MD for an interview with the AMA about the procedure.” 
  • Per MedPage Today,
    • “Vietnam-era military veterans exposed to the weedkiller Agent Orange had a higher risk of developing Parkinson’s disease and other neurodegenerative synucleinopathies, a study of more than 4 million Veterans Affairs (VA) health records showed.
    • “Agent Orange exposure was associated with a 57% greater risk of developing a synuclein-based neurodegenerative disorder (HR 1.57, 95% CI 150-1.63), said Gregory Scott, MD, PhD, of the Oregon Health & Science University (OHSU) and the VA Portland Health Care System, and colleagues.
    • “This included increased risks for Parkinson’s disease (HR 1.44, 95% CI 1.37-1.52), rapid eye movement (REM) sleep behavior disorder (HR 1.78, 95% CI 1.68-1.89), and dementia with Lewy bodies (HR 1.66, 95% CI 1.32-2.09), the researchers reported in JAMA Neurology.”
  • and tells us
    • “Deaths attributable to cancers related to high body mass index (BMI) have more than doubled over the past three decades, according to U.S. data.
    • “Using estimates from the Global Burden of Disease 2023 study, cancer deaths linked to a BMI of 25 or higher increased 104.2%, from 23,236 in 1990 to 47,450 in 2023, reported Digantkumar Patel, MD, of the Springfield Clinic in Illinois.
    • “During this period, the age-standardized death rate increased by 8.1%, from 7.28 to 7.87 per 100,000 people. That uptick indicates that the rise in obesity-related cancer deaths “cannot be explained by population growth and aging alone,” Patel said at the ObesityWeek annual meeting.
    • “We all know about the association between obesity and cancer, but we have less information about how much the burden of these cancers has changed over time,” he noted, suggesting that pinpointing the fastest-growing malignancies can help target screening and prevention.
    • “Our findings reinforce the importance of obesity prevention and treatment as a part of cancer prevention,” Patel added.”
  • Here’s a link to a JAMA special report titled “Toward a Healthier Future Through Obesity Prevention and Care”
  • Health Day informs us,
    • “Three patterns of brain activity can be found among children with ADHD, anxiety or a mix of the disorders
    • “MRI brain scans revealed two distinct types of brain connection problems among kids with the disorders
    • “The two types of brain dysfunction combine in different ways to create the three activity patterns.”
  • and
    • An hourlong memory exam outperforms commonly used 10-minute tests in checking cognitive ability
    • The exam detected mild cognitive impairment in 40% of seniors who were judged normal by the shorter test
    • The longer exam also found dementia in nearly 9% of those who had scored normal.
  • FEHBlog observation: In May 2025, the FEHBlog took a four hour long cognitive ability test and came out with flying colors.
  • The Washington Post points out,
    • “A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a breakthrough year for cancer vaccines.
    • “Patients given the vaccine, galinpepimut-S (GPS), had a 41 percent reduction in risk of death compared to those given other treatments for leukemia, according to Sellas, which presented initial data from a trial of 126 patients.
    • “GPS was tested on patients who achieved a second or later complete remission for leukemia, meaning patients who were successfully treated for the disease at least twice. Acute myeloid leukemia, which affects around 20,000 people a year in the United States, is usually treated with chemotherapy, but remnants of the cancer often remain and recurrence is common.”
  • Per Fierce Pharma,
    • “AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial.
    • “In patients with early Alzheimer’s disease, AriBio’s mirodenafil candidate, AR1001, delivered better clinical outcomes than placebo did—but only in a subgroup of patients who were not on any background therapies such as an acetylcholinesterase inhibitor or memantine, according to results from the Polaris-AD trial.
    • “In the overall population, including those receiving other therapies at baseline, the trial missed statistical significance on change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at week 52. The data were shared at the Clinical Trials on Alzheimer Disease conference in Boston. 
    • “The trial is technically positive, as it’s designed with dual primary populations, each with its separate statistical significance bar. AriBio said it plans to discuss the results with the FDA.”

From the U.S. healthcare business and artificial intelligence front,

  • Kaufmann Hall released its September 2026 National Hospital Flash Report today.
    • “Performance remains tenuous as the external environment pressures hospitals’ financial health. Year-to-date median operating margin dipped to 1.1% in September, when adjusted for allocations. Ongoing challenges, including payer mix, rising bad debt, and charity care, along “with expense growth above the rate of inflation, continue to strain hospitals’ financial health.
    • Bifurcation of hospital performance is becoming more pronounced. The margin gap between higher- and lower-performing hospitals has widened to 19 percentage points, with a historically large portion of hospitals operating at negative or very thin margins. Even slight revenue reductions threaten organizations, which face increasingly difficult decisions on future operations, care delivery, and expense control.
    • “Deliberate, proactive steps can help hospitals build financial resilience. The ongoing migration to outpatient, along with other reimbursement pressures, reinforce the importance of organizations taking a holistic view of operations, including coverage, payer mix, utilization, revenue, cost, service portfolios, and community needs. Strategic decisions made now will help shape how organizations are positioned for the future.
    • “To view more insights on trends affecting hospitals and steps you can consider taking to address them, download the latest issue of the National Hospital Flash Report.”
  • Beckers Payer Issues relates,
    • “Pittsburgh-based Highmark reported $26.5 billion in revenue through the third quarter of 2026.
    • “According to a Nov. 17 news release, Pittsburgh-based Highmark Health had $741 million in operating income and $1.9 billion in net income for that period. Net income includes non-cash gains of $911 million stemming from two completed affiliations: Blue Cross and Blue Shield of Kansas City and Beaver, Pa.-based Heritage Valley Health System.
    • “Top-line revenue growth was $1.9 billion, which included $1.4 billion for Blue KC and $105 million for Heritage Valley. During the first nine months of 2025, revenue was $24.6 billion with $204 million in operating and $69 million in net losses.” 
  • Fierce Healthcare tells us,
    • “Humana is continuing its push to reform prior authorization with the launch of a national provider gold card program.
    • “The program will go into effect on Dec. 1, the company announced Tuesday. It will focus initially on MRI, CT and MRA imaging as well as physical and occupational therapy. Through the program, eligible providers will no longer need to secure a prior authorization approval and can instead use a streamlined process.
    • “Humana estimates that about 50,000 providers will qualify for the program. Eligible providers must be able to demonstrate a proven track record of high-quality care and patient outcomes.”
  • Healthcare Dive informs us,
    • “Name: Dr. Matthew Callstrom
    • “Previous title: Medical director for the strategy department and the artificial intelligence program, Mayo Clinic
    • “New title: Incoming president and chief executive officer, Mayo Clinic
    • “Callstrom will take the reins of the Minnesota-based health system on Jan. 1. 
    • “Since 2002, Callstrom has held various leadership positions at Mayo Clinic, spanning clinical practice, research, strategy and AI. He currently leads the health system’s strategy department and generative AI program, helping shape organizational strategy and efforts to integrate AI into medicine, Mayo said in a press release Friday.
    • “The health system is an early and prominent adopter of AI, using the technology to identify new drugs, detect diseases sooner and support clinical decision-making.
    • “Callstrom will succeed Dr. Gianrico Farrugia, who was CEO for eight years before announcing that he would step down in May.”
  • Beckers Hospital Review points out,
    • “UnitedHealth Group’s pharmacy benefit manager, Optum Rx, has launched three digital tools for members, building on its model designed for more transparency announced earlier in 2026.
    • “According to a Nov. 17 post, Shop MyScript alerts members of savings opportunities soon after a prescription is written. The tool is integrated into the prescribing workflow, allowing members to review options before a prescription is sent to the pharmacy. If a member does not engage, prescriptions are routed to the member’s typical pharmacy.
    • “Eighty-three percent of eligible members have interacted with Shop MyScript since its launch. Optum Rx said average member savings are more than $28 per claim, or script.
    • “Another tool is Optum Price Wise, powered by Fuze Health. When customers are not using health benefits to purchase medications and need to pay with cash, Price Wise shows a full cost breakdown, encompassing the drug price and fees. 
    • “The third tool is Optum Assistant, a conversational AI experience that answers questions about medications, benefits and the pharmacy experience. Optum Assistant intends to efficiently surface information, carry out common tasks and connect to live support if necessary. Optum Rx reported that roughly 80% of these conversations assisted people without requiring further help.”
  • Per STAT News,
    • “For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks. 
    • “Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others.”
    • “We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.”
  • Here’s a link to Fierce Healthcare’s HLTH conference tracker.

Leave a Reply

Your email address will not be published. Required fields are marked *